Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  Kidney (renal cell) cancer
Stage/Subtype:  stage III renal cell cancer
Country:  U.S.A.
Trial Type:  Treatment
Results 1-25 of 51 for your search:
Start Over
Everolimus in Treating Patients with Kidney Cancer Who Have Undergone Surgery
Phase: Phase III
Type: Tissue collection/Repository, Treatment
Age: 18 and over
Trial IDs: S0931, NCI-2011-02028, CDR0000668388, SWOG-S0931, NCT01120249
Nivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 214)
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: CA209-214, NCI-2014-01993, 2014-001750-42, NCT02231749
Stereotactic Radiosurgery in Treating Patients With Kidney Tumors Who are Poor Candidates for Surgery
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: CASE 12806, NCI-2010-01064, NCT00458484
Sorafenib Tosylate and Hypoxia-Activated Prodrug TH-302 in Treating Patients with Advanced Kidney Cancer or Liver Cancer That Cannot Be Removed by Surgery
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: N1153, NCI-2012-00095, CDR0000720022, NCCTG-N1153, NCT01497444
Panobinostat and Everolimus in Treating Patients with Metastatic or Unresectable Renal Cell Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: I 146308, NCI-2009-01599, NCT01037257, NCT01582009
A Phase 1/2 Study to Evaluate MEDI4736
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CD-ON-MEDI4736-1108, NCI-2012-02062, NCT01693562
A Randomized Phase 2 Trial of Axitinib and TRC105 Versus Axitinib Alone in Patients With Advanced or Metastatic Renal Cell Carcinoma
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 105RC101, NCI-2013-01264, NCT01806064
A Study of LY2875358 in Combination With Ramucirumab (LY3009806) in Participants With Advanced Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 15246, NCI-2014-02649, I4C-MC-JTBF, NCT02082210
Safety and Efficay of LAG525 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CLAG525X2101C, NCI-2015-00966, NCT02460224
Low-Dose Chemotherapy, Low-Dose Total-Body Irradiation, and Anti-Thymocyte Globulin Followed By Donor Bone Marrow Transplant in Treating Patients With Hematologic Malignancy or Kidney Cancer
Phase: Phase II
Type: Treatment
Age: Under 70
Trial IDs: MT2001-10, NCI-2010-02155, 2001LS058, UMN-2001LS058, UMN-MT2001-10, NCT00303719
Sunitinib Malate with or without Gemcitabine Hydrochloride in Treating Patients with Advanced Kidney Cancer That Cannot Be Removed by Surgery
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: E1808, NCI-2011-02055, CDR0000681614, ECOG-E1808, NCT01164228
Pazopanib Hydrochloride before Surgery in Treating Patients with Kidney Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CASE 4809, NCI-2010-01392, NCI-2010-01538, NCT01158521
Pazopanib Hydrochloride or Temsirolimus in Treating Patients With Metastatic or Locally Advanced Kidney Cancer
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 2011-0358, NCI-2011-01277, NCT01392183
Everolimus and Bevacizumab in Treating Patients with Advanced Kidney Cancer
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 10-226, NCI-2011-01944, NCT01399918
Pazopanib Hydrochloride before Surgery in Treating Patients with Locally Advanced Kidney Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: LCCC 1028, NCI-2013-00943, 11-0457, NCT01361113
Trebananib with or without Bevacizumab, Pazopanib Hydrochloride, Sorafenib Tosylate, or Sunitinib Malate in Treating Patients with Advanced Kidney Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: PHII-122, NCI-2012-01289, CDR0000738785, P9048_A12PAMDREVW01, 9048, NCT01664182
C-met Inhibitor INCB028060 in Treating Patients with Papillary Kidney Cancer
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 14-C-0037, NCI-2014-02464, 09-25-0099, 140037, 340263, P131324, NCT02019693
A Phase II Trial to Evaluate the Efficacy of AZD6094 (HMPL-504) in Patients With Papillary Renal Cell Carcinoma (PRCC)
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: D5082C00002, NCI-2014-01829, NCT02127710
Stereotactic Body Radiation Therapy Compared to Radiofrequency Ablation in Treating Patients with Localized Kidney Cancer
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: UMCC 2013.069, NCI-2014-01216, 2013.069, HUM00076618, NCT02138578
Stereotactic Ablative Body Radiation Therapy in Treating Patients with Kidney Cancer
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: STU 122013-030, NCI-2014-02122, NCT02141919
A Rollover Protocol for Subjects Previously Treated With AGS-003
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: AGS-003-005, NCI-2011-03808, NCT01482949
Dose-escalation Study of Oral CX-4945
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: C4-08-001, NCI-2009-01571, NCT00891280
Hydroxychloroquine Before Surgery in Treating Patients With Stage I-IV Kidney Cancer
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 19 and over
Trial IDs: 10-029, NCI-2011-02496, NCT01144169
Start Over